Olle Sangfelt's Group
Our hypothesis is that specific ubiquitin ligases (SCFs) occupy critical positions in oncogenic pathways controlling networks of proteins frequently dysregulated in cancer.
The expression and function of proteins change dramatically following the covalent attachment of the small and highly conserved protein ubiquitin (Ub), in a process known as ubiquitylation. Ubiquitylation controls various cellular functions such as cell growth and division, apoptosis, transcription and repair, among others.
A wealth of experimental evidence reveals that aberrant ubiquitylation of cellular regulators directly contributes to the unchecked proliferation, transcription and death typical of cancer cells, and this system has matured as an important cancer drug discovery arena in recent years.
We use interdisciplinary high-throughput functional analysis in combination with translational studies to identify and functionally characterize cancer candidate ubiquitin ligases. The research is particularly focused on oncogenic SCF ligases with key functions in cell cycle control.
One of the main objectives of our basic research is to explore how specific molecular signals converge to modulate SCF activity and substrate specificity. We are also interested to understand how different biological processes control SCF activity to coordinate cellular responses in normal versus cancer cells. Our translational research aims at identifying powerful prognostic and/or treatment predictive markers in cancer, and novel drugs targeting the activity of a specific SCF ligase or the components involved in the conjugation reaction.
|Aldwin Suryo Rahmanto||Postdoc|
|Aljona Maljukova||Senior lab manager|
|Andrä Brunner||PhD student|
|Olle Sangfelt||Senior researcher|
Proteomic screen reveals Fbw7 as a modulator of the NF-κB pathway.
Nat Commun 2012 ;3():976
Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line.
Nature 2001 Sep;413(6853):316-22